Initiation of Novonesis' share buyback program

September 14, 2026
Company announcement No. 17

Today, Novonesis will initiate the first tranche (the "First Tranche") of the EUR 1 billion multi-year share buyback program announced in Company Announcement No. 14, on August 19, 2026. Under the First Tranche, Novonesis will acquire B shares for an aggregate amount of up to EUR 75 million, with the First Tranche expected to end no later than December 17, 2026. Based on the closing share price on September 11, 2026, the First Tranche corresponds to around 1.3 million B shares. The shares acquired under the First Tranche will be used to meet obligations arising from employee share-based incentive programs.

The maximum number of shares acquired by the company per daily market session will be equivalent to no more than 25% of the average volume of shares in the company traded on NASDAQ OMX Copenhagen during the preceding 20 business days. The share buyback program will be conducted in accordance with Article 5 of Regulation (EU) No. 596/2014 (Market Abuse Regulation) and Commission Delegated Regulation (EU) 2016/1052 (the Safe Harbour Rules).

Contact information

Tobias Bjorklund
+45 3077 8682
tobb@novonesis.com

Anders Enevoldsen
+45 5350 1453
adev@novonesis.com

Louise Pugholm Aabo
lspa@novonesis.com

About Novonesis
Novonesis is a global leading biosolutions company transforming the way we all produce, consume and live. In more than 30 industries our biosolutions are helping companies meet their business needs and the needs of our planet. Our 10,000 people worldwide work closely with our partners and customers to challenge conventional thinking and transform business with biology.

Novozymes A/S, part of Novonesis Group
Krogshoejvej 36
2880 Bagsvaerd
Denmark

CVR number: 10 00 71 27 – LEI: 529900T6WNZXD2R3JW38

novonesis.com